CLINUVEL PHARMAC.ADRS1 (F:UR9A) — Market Cap & Net Worth
Market Cap & Net Worth: CLINUVEL PHARMAC.ADRS1 (UR9A)
CLINUVEL PHARMAC.ADRS1 (F:UR9A) has a market capitalization of $302.25 Million (€258.53 Million) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #14935 globally and #1459 in its home market, demonstrating a -2.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CLINUVEL PHARMAC.ADRS1's stock price €5.15 by its total outstanding shares 50200740 (50.20 Million).
CLINUVEL PHARMAC.ADRS1 Market Cap History: 2019 to 2026
CLINUVEL PHARMAC.ADRS1's market capitalization history from 2019 to 2026. Data shows change from $1.02 Billion to $313.99 Million (-15.94% CAGR).
CLINUVEL PHARMAC.ADRS1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CLINUVEL PHARMAC.ADRS1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of UR9A by Market Capitalization
Companies near CLINUVEL PHARMAC.ADRS1 in the global market cap rankings as of May 4, 2026.
Key companies related to CLINUVEL PHARMAC.ADRS1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
CLINUVEL PHARMAC.ADRS1 Historical Marketcap From 2019 to 2026
Between 2019 and today, CLINUVEL PHARMAC.ADRS1's market cap moved from $1.02 Billion to $ 313.99 Million, with a yearly change of -15.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €313.99 Million | -22.46% |
| 2025 | €404.96 Million | -0.72% |
| 2024 | €407.90 Million | -25.75% |
| 2023 | €549.33 Million | -30.15% |
| 2022 | €786.39 Million | -24.01% |
| 2021 | €1.03 Billion | +27.24% |
| 2020 | €813.29 Million | -20.28% |
| 2019 | €1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of CLINUVEL PHARMAC.ADRS1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $302.25 Million USD |
| MoneyControl | $302.25 Million USD |
| MarketWatch | $302.25 Million USD |
| marketcap.company | $302.25 Million USD |
| Reuters | $302.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CLINUVEL PHARMAC.ADRS1
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more